Jun. 1 at 4:00 AM
$ABCL
2)
And the institutional read keeps getting stronger. Goldman accumulated 4.3M shares in a single quarter. Baker Bros increased from 9.1% to 10.8% the day before the Phase 1 readout. An insider made a fresh purchase on May 18, after the data was already out. Cantor Fitzgerald initiated Overweight. Evan Seigerman reiterated Buy. Analyst consensus around
$8-9 against a stock that’s been recovering from well below that.
A drug discovery engine with 203 clinical programs and 14 molecules in clinical stage, and ABCL635 is just the most advanced one right now. AI driven discovery that helped develop bamlanivimab in under 90 days during COVID. The platform generates value whether or not any single program succeeds.
Phase 2 topline data Q3 2026.
$6 billion addressable market with no clean non hormonal solution. A management team with real skin in the game. And a stock that’s been quietly proving the accumulation thesis right.
LONG🚀😉#ABCL
